title: Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
abstract: We have previously reported that botulinum neurotoxin type A (BoNT/A)-specific T-cell responses occur in a majority of patients treated with botulinum neurotoxins (BoNT). In this study, we first determined if T-cell responses against BoNT/A and tetanus toxin (TeNT) differ between cervical dystonia (CD) patients and other movement disorder cases. Secondly, we have examined in CD cases the treatment parameters that may have an effect on the T-cell responses against BoNT/A. We found that T-cell responses to BoNT/A were significantly higher in patients with CD than in those with other movement disorders. An increase in TeNT T-cell response in CD was observed when compared to un-treated controls. CD patients who were injected with BoNT/B mounted higher responses to BoNT/A than patients treated with BoNT/A only. Frequent injections (more than 2.1/year) were associated with a significantly higher T-cell response to BoNT/A in CD. T cell responses to BoNT/A did not differ between CD patients who had clinically responsive and non-responsive status at the time of enrollment.
authors.affiliation: Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Minako
authors.initials: M
authors.lastname: Oshima
authors.forename: Philip R
authors.initials: PR
authors.lastname: Deitiker
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.forename: Drake D
authors.initials: DD
authors.lastname: Duane
authors.forename: K Roger
authors.initials: KR
authors.lastname: Aoki
authors.forename: M Zouhair
authors.initials: MZ
authors.lastname: Atassi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001905:Botulinum Toxins / Q000008:administration & dosage* / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000627:therapeutic use; D002478:Cells, Cultured; D018920:Coculture Techniques; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy / Q000276:immunology*; D009498:Neurotoxins / Q000008:administration & dosage* / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D013744:Tetanus Toxin / Q000008:administration & dosage / Q000627:therapeutic use; D014103:Torticollis / Q000188:drug therapy / Q000276:immunology*; D055815:Young Adult
chemical_list: D009498:Neurotoxins; D013744:Tetanus Toxin; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A